We are delighted to inform you of an important update to our testing panels, effective September 9, 2024.
In an effort to consolidate chemically similar analytes, we are reorganizing our Novel Psychoactive Substances Panel and Novel Emerging Compounds Panel and creating a new Designer Benzodiazepine Panel. This evolution of our designer panels paves the way for detection and addition of new compounds in an ever-changing landscape of emerging designer compounds. Please see below for a brief outline of the expected changes:
– 8-Aminoclonazolam – Removed from Novel Psychoactive Substances Panel
– Adinazolam – Removed from Novel Psychoactive Substances Panel
– Bromazolam – Removed from Novel Emerging Compounds Panel
– Clonazolam – Removed from Novel Psychoactive Substances Panel
– Desalkylgidazepam – Removed from Novel Emerging Compounds Panel
– Etizolam – Removed from Novel Psychoactive Substances Panel
– Flualprazolam – Removed from Novel Psychoactive Substances Panel
– Flubromazepam – Removed from Novel Emerging Compounds Panel
– Flubromazolam – Removed from Novel Psychoactive Substances Panel
For more details on how this update may affect your testing needs, we encourage you to visit our test catalog. There, you will find information about our Designer Panels.
We appreciate your continued trust and partnership with Axis Forensic Toxicology. We look forward to supporting you with our enhanced testing capabilities.
Warm regards,
Matt Zollman
Axis Forensic Toxicology